A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with bendamustine and rituximab for previously untreated chronic lymphocytic leukemia.

Gilles Salles, Paolo Ghia, Bipinkumar Amin et al.|Journal of Clinical Oncology|2014

Cited by 10